Neurocrine reports Q4 adjusted EPS $1.54, consensus $1.14

Reports Q4 revenue $515.2M, consensus $518.13M. “I’m exceptionally proud of the progress we made with INGREZZA last year, helping more patients than ever before treat their tardive dyskinesia. In addition, the positive Phase 3 crinecerfont results for the treatment of congenital adrenal hyperplasia opens the door for us to help patients living with a disabling neuroendocrine disorder,” said Kevin Gorman, Ph.D., CEO of Neurocrine Biosciences. “With a strong foundation in INGREZZA, a potential second important growth driver in crinecerfont, and an advancing pipeline, Neurocrine Biosciences is making significant progress towards becoming a leading neuroscience focused company.”